Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells

Flores-Figueroa, Eugenia; Montesinos, Juan José; Flores-Guzmán, Patricia; Gutiérrez-Espı́ndola, Guillermo; Arana-Trejo, Rosa María; Castillo-Medina, S.; Pérez-Cabrera, Adrián; Hernández-Estévez, Érika; Arriaga, Lourdes; Mayani, Héctor

doi:10.1016/j.leukres.2008.02.013

Cited by 93 publications

(93 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is important to indicate that throughout this study, MSCs were used at the second passage, to avoid cellular heterogeneity in primary cultures. In terms of the immunophenotype, the major antigens described for BM-MSCs, such as CD73, CD105, and CD90 [24,36,37], were also expressed on NCx-and CeCaderived MSCs. CD13 expression was high and homogeneous in all samples from the three sources, as we previously reported for cord blood-and placenta-derived MSCs [24]; thus, CD13 could represent a specific marker for MSCs from several sources, including the cervix.…”

mentioning

confidence: 99%

In Vitro Evidence of the Presence of Mesenchymal Stromal Cells in Cervical Cancer and Their Role in Protecting Cancer Cells from Cytotoxic T Cell Activity

Montesinos

Mora‐García²,

Mayani

et al. 2013

Stem Cells and Development

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

In Vitro Evidence of the Presence of Mesenchymal Stromal Cells in Cervical Cancer and Their Role in Protecting Cancer Cells from Cytotoxic T Cell Activity

Montesinos

Mora‐García²,

Mayani

et al. 2013

Stem Cells and Development

Self Cite

View full text Add to dashboard Cite

“…normal with respect to the ability of sustaining the growth of CD34 + cells in co-cultures and secretion of normal levels of cytokines and growth factors (TNF-α, IL-6, stem cell factor, GM-CSF, VEGF, collagen and fibronectin) [24,25] some other studies show that MDS-MSCs are unable to support hematopoiesis [16][17][18][19][20][21][22][23]. Further, some studies have shown that the MSCs of MDS secrete increased levels of certain cytokines such as TNFα, IL-6, IFN-γ and angiogenic cytokines [17,18].…”

Section: Journal Of Molecular and Genetic Medicinementioning

confidence: 99%

“…MDS derivation may be a multi step process, but believed to be originated at the hematopoietic stem/progenitor level [6,[19][20][21][22][23][24][25]. The cell type which should be considered as anMDS "stem" cell is yet to be disclosed.…”

Section: The Occurrence Of Cytogenetic Abnormalities In Mdshscsmentioning

confidence: 99%

“…Some studies indicate that MSCs derived from MDS are cytogenetically normal [25] while others in their studies have shown that MDS-MSCs show chromosomal abnormalities [24,[44][45][46]. The percentage of presence of structural chromosomal aberrations in MDS derived MSCs is found to be low in some studies [44,45] while there are other reports that claim for higher rates of having abnormal MSCs in MDS [22,46].…”

Section: The Origin Of Cytogenetic Abnormalities In Mds-mscsmentioning

confidence: 99%

See 1 more Smart Citation

Development of Cytogenetic Abnormalities in Myelodysplastic Syndromes

WMMS¹,

AJIS²

2016

J Mol Genet Med

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia and peripheral cytopenias. Research into MDS have found that both hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) in the nurturing niche of HSCs are genetically altered in MDS. In this review we present the existing views on the origin of cytogenetic abnormalities in HSC and MSC compartments in MDS. Based on the available data, we speculate that the origin of the chromosomal aberrations of the hematopoietic compartment occurs at the hematopoietic stem/ progenitor level. The genetic aberrations in MSC compartment appears to initiate independently from their hematopoietic counterparts. Whether the genetic events in both HSC and MSC compartments which lead to MDS occur simultaneously or at different time points in the disease development need to be determined in future.

show abstract

“…In co-culture with primitive hematopoietic cells, various stromal cell types including AGMs, fetal liver, and bone marrow stromal cells, endothelial cells, and mesenchymal stem cells (MSCs) promote HSC expansion [67,68,71,[81][82][83][84][85]112,113]. MSCs promote expansion through cell-to-cell contact [114] and cytokine production [115]. Exogenous supplementation or forced expression of HSC-supportive factors in MSCs promotes ex vivo expansion of HSCs [116,117].…”

Section: Hsc-mesenchymal Stromal Cell Co-culturementioning

confidence: 99%

Ex vivo expansion of hematopoietic stem cells

Xie

Zhang

2015

Sci. China Life Sci.

View full text Add to dashboard Cite

Ex vivo expansion of hematopoietic stem cells (HSCs) would benefit clinical applications in several aspects, to improve patient survival, utilize cord blood stem cells for adult applications, and selectively propagate stem cell populations after genetic manipulation. In this review we summarize and discuss recent advances in the culture systems of mouse and human HSCs, which include stroma/HSC co-culture, continuous perfusion and fed-batch cultures, and those supplemented with extrinsic ligands, membrane transportable transcription factors, complement components, protein modification enzymes, metabolites, or small molecule chemicals. Some of the expansion systems have been tested in clinical trials. The optimal condition for ex vivo expansion of the primitive and functional human HSCs is still under development. An improved understanding of the mechanisms for HSC cell fate determination and the HSC culture characteristics will guide development of new strategies to overcome difficulties. In the future, development of a combination treatment regimen with agents that enhance self-renewal, block differentiation, and improve homing will be critical. Methods to enhance yields and lower cost during collection and processing should be employed. The employment of an efficient system for ex vivo expansion of HSCs will facilitate the further development of novel strategies for cell and gene therapies including genome editing. ex vivo expansion, hematopoietic stem cells, niche, signal transduction, cord blood, transplantation, SCID-repopulating cell, genome editing, CRISPR/Cas9 Citation:Xie JJ, Zhang CC. Ex vivo expansion of hematopoietic stem cells.

show abstract

Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells

Cited by 93 publications

References 51 publications

In Vitro Evidence of the Presence of Mesenchymal Stromal Cells in Cervical Cancer and Their Role in Protecting Cancer Cells from Cytotoxic T Cell Activity

In Vitro Evidence of the Presence of Mesenchymal Stromal Cells in Cervical Cancer and Their Role in Protecting Cancer Cells from Cytotoxic T Cell Activity

Development of Cytogenetic Abnormalities in Myelodysplastic Syndromes

Ex vivo expansion of hematopoietic stem cells

Contact Info

Product

Resources

About